Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells.
Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover Image Legend - p. iii 7. Aims and Scope - p. iii 8. About the Editors - p. ix 9. Preface - p. xi 10. Contributors - p. xxiii 11. Part I: NK cells: General properties - p. xxvii 12. Chapter 1. NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms - p. 3 13. Chapter 2. Challenges for NK cell-based therapies: What can we learn from lymph nodes? - p. 33 14. Chapter 3. NK cells and oncolytic viruses in cancer therapy - p. 53 15. Chapter 4. Successes and challenges of NKT cell immunotherapy: Breaking tolerance to cancer resistance - p. 70 16. Part II: Activation of NK cells - p. 80 17. Chapter 5. The role of peptidases and their endogenous inhibitors in the regulation of NK cell cytotoxicity - p. 83 18. Chapter 6. Novel strategies to expand supercharged NK cells with augmented capacity to withstand inactivation by tumors - p. 101 19. Chapter 7. NK cell-mediated immunotherapy: The exquisite role of PGC-1a in metabolic reprogramming - p. 121 20. Chapter 8. IL-15 and IL-15Rα: Something old, something new, and something blue - p. 143 21. Part III: Induction of NK cells from stem cells - p. 161 22. Chapter 9. Advances in pluripotent stem cell-derived natural killer cells for cancer immunotherapy - p. 165 23. Chapter 10. Phenotypic plasticity: The emergence of cancer stem cells, collective cell migration, and the impact on immune surveillance - p. 183 24. Part IV: CAR-NK cells in immunotherapy - p. 190 25. Chapter 11. Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy - p. 193 26. Chapter 12. CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product - p. 219 27. Part V: Targeting NK cells - p. 230 28. Chapter 13. Regulation of NKG2D by RKIP: Implications on NK-mediated cytotoxicity and cytokine production - p. 233 29. Chapter 14. Checkpoint inhibition in the fight against cancer: NK cells have some to say in it - p. 271 30. Chapter 15. The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies - p. 325 31. Chapter 16. Immunometabolic targeting of NK cells to solid tumors - p. 349 32. Chapter 17. Targeting metabolism to potentiate NK cell-based therapies - p. 369 33. Chapter 18. New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors - p. 387 34. Part VI: NK immunotherapy in various cancers - p. 402 35. Chapter 19. Adoptive NK cell therapies in children with cancer: Clinical challenges and future possibilities - p. 425 36. Chapter 20. NK cells in prostate cancer - p. 439 37. Chapter 21. Involvement of natural killer cells in the pathogenesis of lymphomas: Therapeutic implications - p. 459 38. Chapter 22. NK cells in brain tumors: From biology to treatment - p. 485 39. Index - p. 503
Successes and Challenges of NK Immunotherapy: Increasing Anti-tumor Efficacy describes the unique therapeutic applications of NK cells to fight cancers and eliminate the bulk and subset of cancer stem cells responsible for metastasis, relapse and recurrences. The book provides information on the development, engineering, mechanisms of action, response to various preclinical models, and applications in various clinical trials. Sections cover the development of highly engineered cytotoxic NK cells, their mechanisms of action, preclinical and clinical applications, the development and application of CAR-NK cells, and new NK-drug conjugates, also emphasizing that activated NK cells can target and kill highly resistant cancer stem cells.
Written by the leading experts on NK immunotherapy worldwide, this is a valuable resource for researchers, clinicians and members of the biomedical field who are interested in understanding novel and efficient therapies to fight cancers.
1. Title of Book - p. i 2. Cover image - p. i 3. Title page - p. ii 4. Table of Contents - p. iii 5. Copyright - p. iii 6. Cover Image Legend - p. iii 7. Aims and Scope - p. iii 8. About the Editors - p. ix 9. Preface - p. xi 10. Contributors - p. xxiii 11. Part I: NK cells: General properties - p. xxvii 12. Chapter 1. NK cells and CD8 T cells in cancer immunotherapy: Similar functions by different mechanisms - p. 3 13. Chapter 2. Challenges for NK cell-based therapies: What can we learn from lymph nodes? - p. 33 14. Chapter 3. NK cells and oncolytic viruses in cancer therapy - p. 53 15. Chapter 4. Successes and challenges of NKT cell immunotherapy: Breaking tolerance to cancer resistance - p. 70 16. Part II: Activation of NK cells - p. 80 17. Chapter 5. The role of peptidases and their endogenous inhibitors in the regulation of NK cell cytotoxicity - p. 83 18. Chapter 6. Novel strategies to expand supercharged NK cells with augmented capacity to withstand inactivation by tumors - p. 101 19. Chapter 7. NK cell-mediated immunotherapy: The exquisite role of PGC-1a in metabolic reprogramming - p. 121 20. Chapter 8. IL-15 and IL-15Rα: Something old, something new, and something blue - p. 143 21. Part III: Induction of NK cells from stem cells - p. 161 22. Chapter 9. Advances in pluripotent stem cell-derived natural killer cells for cancer immunotherapy - p. 165 23. Chapter 10. Phenotypic plasticity: The emergence of cancer stem cells, collective cell migration, and the impact on immune surveillance - p. 183 24. Part IV: CAR-NK cells in immunotherapy - p. 190 25. Chapter 11. Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy - p. 193 26. Chapter 12. CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product - p. 219 27. Part V: Targeting NK cells - p. 230 28. Chapter 13. Regulation of NKG2D by RKIP: Implications on NK-mediated cytotoxicity and cytokine production - p. 233 29. Chapter 14. Checkpoint inhibition in the fight against cancer: NK cells have some to say in it - p. 271 30. Chapter 15. The dual role of Natural Killer cells during tumor progression and angiogenesis: Implications for tumor microenvironment-targeted immunotherapies - p. 325 31. Chapter 16. Immunometabolic targeting of NK cells to solid tumors - p. 349 32. Chapter 17. Targeting metabolism to potentiate NK cell-based therapies - p. 369 33. Chapter 18. New therapeutic modalities in breast cancer by targeting NK cell inhibitory and activating receptors - p. 387 34. Part VI: NK immunotherapy in various cancers - p. 402 35. Chapter 19. Adoptive NK cell therapies in children with cancer: Clinical challenges and future possibilities - p. 425 36. Chapter 20. NK cells in prostate cancer - p. 439 37. Chapter 21. Involvement of natural killer cells in the pathogenesis of lymphomas: Therapeutic implications - p. 459 38. Chapter 22. NK cells in brain tumors: From biology to treatment - p. 485 39. Index - p. 503
